Biotechnology

OPM released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 182.16 M, actual EPS CNY 0.07

OPM to Release FY2026 Q1 Earnings Report on April 23 After-Market BJT

OPM to Release FY2025 Earnings on April 23 Pre-Market (BJT), Forecast Revenue CNY 375.5 M, EPS CNY 0.64

OPM released FY2025 Annual Earnings on February 27 Pre-Market (BJT), actual revenue CNY 354.91 M (forecast CNY 375.5 M), actual EPS CNY 0.37 (forecast CNY 0.64)

OPM released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 83.39 M, actual EPS CNY -0.0678

OPM released FY2025 9 Months Earnings on October 29 During-Market (BJT), actual revenue CNY 271.53 M, actual EPS CNY 0.4307

OPM released FY2025 Q3 earnings on October 29 During-Market (BJT), actual revenue CNY 93.78 M, actual EPS CNY 0.1012

OPM FY2025 Q3 Earnings Release on October 30 During-Market BJT

OPM released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue CNY 94.07 M, actual EPS CNY 0.1994

OPM released FY2025 Semi-Annual earnings on August 22 After-Market (BJT), actual revenue CNY 177.75 M, actual EPS CNY 0.33

OPM to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Oupumai's Net Profit Expected to Grow by 53.28% in the First Half of 2025

AUPHMY's stock price rises, analysts give buy rating

Auphime Shares Surge 11.74%, Rated 'Buy' by KSY Research

AUPHMY Plans to Acquire Pengli Biologics Equity

AUPHIRM Announces Q1 2025 Earnings: Revenue Up but Profits Down

OPM released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 83.68 M, actual EPS CNY 0.13

OPM to Release FY2025 Q1 Earnings Report on April 29 After-Market BJT

OPM to Release FY2024 Annual Earnings on April 16, 2025 (BJT), Forecast Revenue 305.7 M CNY, EPS 0.435 CNY

OPM released FY2024 Q4 earnings on February 27, 2025 (BJT), with actual revenue of CNY 81.39 M and EPS of CNY -0.0601

688293

OPM's wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd., recently successfully passed the European Union Quality Authorised Person (QP) audit and received a compliance audit report. This marks that Silun Biotechnology's quality management system meets the requirements of EU GMP regulations, providing assurance for its research and production services in the field of macromolecular biopharmaceuticals, and laying the foundation for expanding into international markets such as the EU

Zhitong

OPM's subsidiary passes EU QP audit

000739

603456

603127

06127

688602

CRO concept stocks fluctuated upward, Jiuzhou Pharma hit the daily limit, APELOA rose over 5%, JOINN, Chemspec, OPM, and Haoyuan Pharma followed suit

APELOA

Jiuzhou Pharma

JOINN

Chemspec

CRO concept stocks fluctuate and rise, Jiuzhou Pharma hits the limit up

002340

301296

002439

600166

600755

On September 2nd, a total of 6 listed companies had their restricted shares unlocked, with a total market value of approximately 5.525 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares FOTON 600166 Additional A Shares Original Shareholders Allocation Listed 1.429 billion ITG 600755 Equity Incentive Restricted Circulation 396,100 GEM 002340 Equity Incentive Restricted Circulation 8.7545 million VENUSTECH 002439 Equity Incentive Restricted Circulation 988,700 NJF 301296 Pre-issuance Shares Restricted Circulation 17.136 million OPM 688293 3.61394 million

VENUSTECH

FOTON

Zhitong A-share lock-up release overview | September 2

OPM announced that it expects to achieve a net profit of approximately 37 million yuan attributable to the owners of the parent company in the first half of 2025, representing a year-on-year increase of 53.28%. During the reporting period, the company's product business segment saw significant revenue growth, with a year-on-year increase of over 25%, and more than 50% growth in the second quarter. The growth in performance is mainly attributed to the company's continuous R&D innovation and market expansion in the field of cell culture products, with products gaining wide recognition in both domestic and international markets

OPM: Expected net profit of approximately 37 million yuan in the first half of the year, a year-on-year increase of 53.28%

688488

300485

688062

688136

The biopharmaceutical sector continues to adjust, with *ST Four Rings hitting the daily limit down, Rongchang Bio falling over 18%, and Mabwell, SDKX, Science Sun Pharm, OPM, Aidea Pharma, and others following suit

Aidea Pharma

Science Sun Pharm

Mabwell

SDKX

REMEGEN

OPM plans to acquire 100% equity of Pengli Biotechnology from 31 counterparties through the issuance of shares and cash payment, with a transaction price of 1.451 billion yuan. This transaction will help the company introduce preclinical research client resources, expand the potential customer base, and enhance the early research and development pipeline, strengthening the commercialization prospects of innovative drugs

OPM plans to issue shares to acquire 100% equity of Pengli Bio at a transaction price of 1.451 billion yuan

According to the Zhitong Finance APP, OPM disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 83.68 million yuan, a year-on-year increase of 4.98%; net profit attributable to the parent company was 14.67 million yuan, a year-on-year decrease of 25.08%; and net profit excluding non-recurring items was 10.80 million yuan, a year-on-year decrease of 33.06%. Basic earnings per share were 0.13 yuan

OPM released its first-quarter performance, with a net profit attributable to the parent company of 14.67 million yuan, a year-on-year decrease of 25.08%

OPM released its 2024 annual performance, with operating revenue of 297 million yuan, a year-on-year increase of 22.26%. The net profit attributable to the parent company was 21.0523 million yuan, a year-on-year decrease of 61.04%; the net profit after deducting non-recurring gains and losses was 6.5859 million yuan, a year-on-year decrease of 81.03%. The basic earnings per share were 0.19 yuan/share, and it is proposed to distribute a cash dividend of 2.00 yuan (including tax) for every 10 shares

OPM released its 2024 annual performance, with a net profit attributable to the parent company of 21.0523 million yuan, a year-on-year decrease of 61.04%

According to the Zhitong Finance APP, OPM announced that its shareholder Ningbo Meishan Bonded Port Area Huajie Equity Investment Management Co., Ltd. - Huajie (Tianjin) Medical Investment Partnership (Limited Partnership) (referred to as "Huajie Investment") will reduce its holdings of the company's shares by a total of 3.4065 million shares through block trading and centralized bidding from January 8, 2025, to March 31, 2025. The total number of shares reduced accounts for 3% of the company's current total share capital, and this reduction plan has been completed

OPM shareholder Huajie Investment has completed a 3% share reduction

OPM's major shareholder, Huajie Investment, reduced its holdings by 1.124 million shares through centralized bidding and block trading from February 11 to March 10, 2025, with a reduction ratio of 0.99%

OPM's major shareholder Huajie Investment reduced its holdings by 1.124 million shares

OPM(688293.SH)